| Trial ID: | L5864 |
| Source ID: | NCT02686476
|
| Associated Drug: |
Empagliflozin
|
| Title: |
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
|
| Acronym: |
E-LIFT
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Non Alcoholic Fatty Liver Disease
|
| Interventions: |
DRUG: Empagliflozin
|
| Outcome Measures: |
Primary: Change in Liver Fat, To evaluate the change in liver fat content at baseline and 3 Months, 3 Months | Secondary: Pancreatic fat content, To evaluate the changes in pancreatic fat content at baseline and 3 Months, 3 Months|visceral fat, To evaluate the changes in visceral fat content at baseline and 3 Months, 3 Months|subcutaneous fat, To evaluate the changes in subcutaneous fat content at baseline and 3 Months, 3 Months
|
| Sponsor/Collaborators: |
Sponsor: Medanta, The Medicity, India
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
100
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2016-03
|
| Completion Date: |
2017-12
|
| Results First Posted: |
|
| Last Update Posted: |
2019-08-15
|
| Locations: |
Division Of Endocrinology , Medanta The Medicity Sec 38, Gurgaon, Haryana, 122001, India
|
| URL: |
https://clinicaltrials.gov/show/NCT02686476
|
